Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

“We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.”

Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.”

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc.
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for

Read more

Regenerative Medicine Market Futuristic Comprehensive Insights with COVID-19 Impact Analysis | Organogenesis Inc, Osiris Therapeutics Inc

The MarketWatch News Department was not involved in the creation of this content.

Nov 29, 2020 (MarketResearch.biz via Comtex) —
A consciously conceived and designed business intelligence report titled Global Regenerative Medicine market 2020 by Manufacturers, Type, and Application, Forecast to 2029 by MarketResearch.biz discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Regenerative Medicine market which is marking on the enlargement and opening doors for outlook growth in the coming years.

This is the latest report, covering the current COVID-19/Corona Virus pandemic impact on the market which has affected every aspect of life globally. This has brought along several changes in market conditions and the Business areas. The rapidly changing market scenario and initial and future assessment of the impact are covered in the Regenerative Medicine market report. 

For All-Inclusive Information: Download a FREE sample copy of Regenerative Medicine Market Report Study 2020-2029 at https://marketresearch.biz/report/regenerative-medicine-market/request-sample

(Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, list of tables and figures, Impact Analysis of COVID-19, TOC, an outlook to key players of the market and comprising key regions.)

Competitive Analysis:

The major companies are exceedingly focused on innovation in Regenerative Medicine production technology to enhance ledge life and efficiency. The best long-term development path for Regenerative Medicine market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.

Key manufacturers are included based on the company profile, sales data and product specifications, etc: Organogenesis Inc, Osiris Therapeutics Inc, Pfizer Inc, Novartis AG, Vericel Corporation, NuVasive Inc, Cook Biotech Inc, GlaxoSmithKline plc., Boehringer Ingelheim GmbH, Amgen Inc

Each manufacturer or Regenerative Medicine market player’s growth rate, gross profit margin, and revenue figures is provided in a tabular, simple format for few years and an individual section on Regenerative Medicine market recent development such as collaboration, mergers, acquisition, and any new service or new product launching in the market is offered.

Regenerative Medicine Market Segmentation Outlook By therapy, product type, application, and region:

By therapy: Cell Therapy Tissue Engineering Immunotherapy Gene Therapy By product type: Cell-Based Products Allogeneic Products Autologous Products Acellular Products By application: Orthopedic & Musculoskeletal Disorders Dermatology Cardiology Dermatology Diabetes Central Nervous System Disorders Others

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Regenerative Medicine Market: https://marketresearch.biz/report/regenerative-medicine-market/covid-19-impact

Regional Analysis:On the idea of geography, the Regenerative Medicine Market report covers statistics for a couple of geographies inclusive of, North America (U.S., Mexico, Canada) South America (Argentina, Brazil) The Middle East & Africa (South Africa, Saudi Arabia) Asia-Pacific (China, Japan, India, Southeast Asia) Europe (U.K., Spain, Italy, Germany, France, Russia)

In addition, The following years considered for this study to forecast the global Regenerative Medicine market size are as follows:

– Actual Year: 2019

– Estimated Year: 2020

– Forecast Year: 2020–2029

Some Fundamental Report Highlights:

– Thorough Outline

Read more

VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

 

Source Article

Read more

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005064/en/

Dr Suhail Nurbhai. High-resolution images available on request. (Photo: Business Wire)

Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. He joins Mission from VHsquared, where he held the position of CMO since 2014.

Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe. He joined Shionogi from Takeda where he was Vice President and Head of Clinical and Analytical Science in Europe, with responsibility for all Clinical Science activities in Neurosciences, Cardiovascular/Renal/Metabolic, Oncology, Gastrointestinal/Genitourinary and Respiratory Medicine, as well as Clinical Pharmacology, Medical Writing, Statistics and Data Management.

Suhail’s initial industry experience was at Pfizer, where he spent 12 years, initially in Sandwich, UK and then at Global R&D Headquarters in Connecticut, USA. During his time at Pfizer he held roles of increasing responsibility across multiple therapeutic areas including GI/GU, anti-bacterial, sexual medicine and anti-fungal, prior to completing his time at Pfizer as Head of Neuroscience Clinical R&D at the Groton site in Connecticut.

During his career he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US, and achieved multiple successful NDA and MAA submissions and approvals.

Suhail qualified in Medicine at Dundee University in Scotland and completed his post-graduate medical training at Hope Hospital in the University of Manchester.

Commenting on the appointment, Dr Anker Lundemose, CEO of Mission Therapeutics said: “We are pleased to be welcoming Suhail to further strengthen Mission’s leadership team. His in-depth knowledge and proven track record in clinical research will be invaluable as we work to bring our first-in-class USP30 inhibitor compound into the clinic. Suhail’s appointment is the last of a series of organisational changes, including the promotions of Dr Paul Thompson and Dr Nick Edmunds, to ready the Company for this next phase.”

Dr Suhail Nurbhai added: “It’s great to be joining Mission at such an exciting time for the Company. The ongoing collaboration with AbbVie and recently signed agreement with Pfizer represent solid industry validation of the Company’s approach and ground-breaking technology. I look forward to building on this success progressing its lead assets into the clinic.”

– ENDS –

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong

Read more

First-Ever Treatment Shown to Reverse Alzheimer’s Earns NeuroEM Therapeutics FDA Breakthrough Device Status

The FDA is expediting a revolutionary clinical-stage head device to beat back Alzheimer’s disease at home

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005376/en/

Woman pictured wearing NeuroEM Therapeutics’ bioengineered MemorEM™ cap and arm control box. This revolutionary head device has earned FDA Breakthrough Device designation, having demonstrated in a pilot study that it can reverse Alzheimer’s disease. This woman’s participation in the study resulted in her regaining the equivalent of 12 months of memory. (Photo: Business Wire)

“No other drug or device has received this highest FDA designation to accelerate a treatment for Alzheimer’s disease,” said Dr. Robert Matthews, PhD, CEO of NeuroEM Therapeutics. “No other treatment has demonstrated the clinical results we have thus far, to not only slow but in fact reverse the progressive, debilitating loss of memory caused by this devastating brain disease.”

The FDA has given Breakthrough status to over 300 devices and over 100 drugs, but none to a therapeutic for Alzheimer’s disease – until now. NeuroEM’s head device (MemorEMTM) is the first-ever Alzheimer’s treatment (device or drug) to receive FDA Breakthrough status. The FDA program is designed to expedite the development and review process of new technology for patients with life-threatening or irreversibly debilitating conditions, such as Alzheimer’s Disease.

  • NeuroEM’s novel, proprietary technology, called Transcranial Electromagnetic Treatment (TEMT), achieves what other treatments for AD have not. In fact, no other therapy comes close to MemorEM’s remarkable results, made possible by its unique modes of action.

  • In just two months of daily use, the MemorEM restored on average the equivalent of 12 months of memory for 7 of 8 participants in its pilot study, none of whom experienced adverse side effects.

  • Treatment is easy, comfortable and safe. A patient wears what appears to be a simple cap that belies the complex biomedical engineering within it. The device is worn twice a day in home for an hour at a time, and its design allows the patient to move around home as usual.

NeuroEM has pioneered TEMT to successfully penetrate the skull to reach vital nerve cells in the brain called neurons. NeuroEM’s revolutionary TEMT technology works by breaking up small aggregates (oligomers) of two toxic proteins, called β-amyloid and tau, that are made inside the brain’s neurons during the Alzheimer’s disease process. These two toxic oligomers appear to be the root cause of Alzheimer’s disease by wreaking havoc on vital functions within neurons – especially in brain areas involved in memory. The electromagnetic waves emanating from multiple emitters within NeuroEM’s MemorEM head device easily penetrate the human brain and gently disassociate the toxic oligomers inside neurons resulting in a reversal of Alzheimer’s memory impairment in key

Read more

Company Profile for Guided Therapeutics, Inc.

Guided Therapeutics, Inc. (OTCQB: GTHP) has developed a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The company’s first product, LuViva™, is a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, LuViva was able to detect cervical cancer up to two years earlier than conventional tests. LuViva is designed to provide an objective result at the point-of-care, thereby improving the management of cervical disease: www.guidedinc.com.

Company:

Guided Therapeutics, Inc.

 

 

Headquarters Address:

5835 Peachtree Corners East

 

Suite B

 

Norcross, GA 30092

 

 

Main Telephone:

770-242-8723

 

 

Website:

www.guidedinc.com

 

 

Ticker/ISIN:

GTHP(OTCQB)/US40171F1057

 

 

Type of Organization:

Public

 

 

Industry:

Medical Devices

 

 

Key Executives:

CEO: Gene Cartwright

 

COO: Mark Faupel

 

 

Investor Relations

 

Contact:

Mark Faupel

Phone:

770-242-8723

Email:

[email protected]

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005704/en/

Source Article

Read more

Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium

NEW YORK, Oct. 20, 2020 /PRNewswire/ — Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.

(PRNewsfoto/Phosplatin Therapeutics LLC)
(PRNewsfoto/Phosplatin Therapeutics LLC)

Title: 

PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)

Abstract availability: 

Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site

Session: 

New Drugs Poster Session (code 380)

Lead Author: 

A. Anel, University of Zaragoza /Aragón Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain

Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. “The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112’s pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important,” said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. “We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain.”

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won “Best Poster” within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112’s pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company’s lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of

Read more